Merck KGaA and Schüssler Novachem Reach Agreement on Sale of Assets of Chemische Fabrik Lehrte

Merck KGaA and Schüssler Novachem Reach Agreement on Sale of Assets of Chemische Fabrik Lehrte 
 
• Merck KGaA sells laboratory equipment and production units to Schüssler 
Novachem 
• Merck KGaA to exit Lehrte site as planned at the end of June 
 
Darmstadt, Germany, June 12 – Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors, and Schüssler Novachem, a manufacturer of inorganic salts based in Halle/Saale, Germany, have reached an agreement on the sale of laboratory equipment and production units located at the Lehrte site in the German federal state of Lower Saxony. The parties have agreed not to disclose the selling price or further details of the transaction. Schüssler had already acquired the land and buildings in Lehrte from Deutsche Bahn Immobilien GmbH in a separate transaction. 
 
"We are glad to see that Schüssler will continue with their own chemical production at the Lehrte location," said Bernd Reckmann, CEO Chemicals at Merck KGaA, Darmstadt, Germany. 
 
As part of its "Fit for 2018" transformation and growth program, Merck KGaA announced in 2012 that it would close the Lehrte site in mid-2014 and continue to operate the relevant business from Darmstadt. Therefore Merck KGaA, Darmstadt, Germany and the works council agreed about a reconciliation of interest and a social plan. Apart from efficiency enhancement measures, "Fit for 2018" also comprises numerous investments to secure future growth across various segments of the business: a recent example of supporting growth has been the construction of new powerplants at Merck KGaA's corporate center in Darmstadt since August 2013. 
 

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.